Dena R Howard (D R Howard, Dena Howard)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2022
Publications (10 Years): 6

Top Venues

British journal of haematology

Leukemia

Blood advances

Trials

University of Leeds

University of Leeds (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Leeds Sep 01 2004

United Kingdom

Principal Statistician :: Leeds Institute of Clinical Trials Research

University of Sheffield Jan 01 2002 - Aug 31 2004

United Kingdom

Statistical Consultant :: Probability and Statistics

Education History

University of Leeds Oct 01 2012 - Nov 19 2018

United Kingdom

PHD :: Leeds Institute of Clinical Trials Research

University of Sheffield Sep 01 2000 - Aug 31 2001

United Kingdom

MSC :: Probability and Statistics

University of Leeds Sep 15 1997 - Jul 15 2000

United Kingdom

BSC :: Mathematics

Publications

Tahla Munir, Jake Emmerson, Anna Hockaday, Jamie B Oughton, Dena R Howard, David Phillips, Jeff Neilson, Nicholas Pemberton, Shankara Paneesha, Ben Kennedy, Andy Rawstron, Peter Hillmen
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British journal of haematology 199 (5) (2022)
Dena R Howard, Anna Hockaday, Julia M Brown, Walter M Gregory, Susan Todd, Tahla Munir, Jamie B Oughton, Claire Dimbleby, Peter Hillmen
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Trials 22 (1) (2021)
David John Allsup, Dena R Howard, Jake Emmerson, Anna Hockaday, Andy Rawstron, Jamie B Oughton, Adrian Bloor, David Phillips, Amit Nathwani, Shankara Paneesha, Deborah Turner, Talha Munir, Peter Hillmen
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British journal of haematology 194 (3) (2021)
Tomasz K Wojdacz, Harindra E Amarasinghe, Latha Kadalayil, Alice Beattie, Jade Forster, Stuart J Blakemore, Helen Parker, Dean Bryant, Marta Larrayoz, Ruth Clifford, Pauline Robbe, Zadie A Davis, Monica Else, Dena R Howard, Basile Stamatopoulos, Andrew J Steele, Richard Rosenquist, Andrew Collins, Andrew R Pettitt, Peter Hillmen, Christoph Plass, Anna Schuh, Daniel Catovsky, David G Oscier, Matthew J J Rose-Zerilli, Christopher C Oakes, Jonathan C Strefford
Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. Blood advances 3 (16) (2020)
Dena R Howard, T Munir, L McParland, Andrew C Rawstron, D Milligan, A Schuh, A Hockaday, David John Allsup, S Marshall, A S Duncombe, J L O'Dwyer, A F Smith, R Longo, A Varghese, P Hillmen
Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia 31 (11) (2017)
Abraham M Varghese, Dena R Howard, Christopher Pocock, Andy C Rawstron, George Follows, Helen McCarthy, Claire Dearden, Christopher Fegan, Donald Milligan, Alexandra F Smith, Walter Gregory, Peter Hillmen, null null
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. British journal of haematology 176 (4) (2016)

Dena R Howard.css-eqlu8i{font-size:small;padding-left:4px;} (D R Howard, Dena Howard)

Publication Activity (10 Years)

Top Topics

Top Venues

Dena R Howard (D R Howard, Dena Howard)